Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …

Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10%
in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk …

Introduction Neoadjuvant therapy may improve survival compared with upfront surgery in
patients with resectable and borderline resectable pancreatic cancer, but high-quality …

The lysyl oxidase family represents a promising target in stromal targeting of solid tumors
due to the importance of this family in crosslinking and stabilizing fibrillar collagens and its …

Importance Clinical outcomes after curative treatment of resectable pancreatic ductal
adenocarcinoma (PDA) remain suboptimal. To assess the potential of early control of …

Abstract Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an
indicator of aberrant glycosylation in pancreatic cancer. CA19-9 functions as a biomarker …

Pancreatic cancer is likely to become the second most frequent cause of cancer-associated
mortality within the next decade. Surgical resection with adjuvant systemic chemotherapy …

The opportunity to detect pancreatic cancer (PC) when potentially curable depends on early
diagnosis and an ability to identify and screen high-risk populations before symptoms arise …

Pancreatic cancer is one of the solid tumors with the worst prognosis. Five-year survival rate
is less than 10%. Surgical resection is the only potentially curative treatment, but the tumor is …

Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for
patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases …